- Home
- BCDA vs CARM Comparison
BCDA vs CARM Comparison
Compare BCDA & CARM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- CARM
- Stock Information
- Founded
- BCDA N/A
- CARM 2016
- Country
- BCDA United States
- CARM United States
- Employees
- BCDA N/A
- CARM N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- CARM Biotechnology: Pharmaceutical Preparations
- Sector
- BCDA Health Care
- CARM Health Care
- Exchange
- BCDA Nasdaq
- CARM Nasdaq
- Market Cap
- BCDA 11.3M
- CARM 12.1M
- IPO Year
- BCDA N/A
- CARM N/A
- Fundamental
- Price
- BCDA $1.35
- CARM $0.26
- Analyst Decision
- BCDA Strong Buy
- CARM Hold
- Analyst Count
- BCDA 1
- CARM 5
- Target Price
- BCDA $25.00
- CARM $0.90
- AVG Volume (30 Days)
- BCDA 1.6M
- CARM 1.1M
- Earning Date
- BCDA 11-12-2025
- CARM 11-06-2025
- Dividend Yield
- BCDA N/A
- CARM N/A
- EPS Growth
- BCDA N/A
- CARM N/A
- EPS
- BCDA N/A
- CARM N/A
- Revenue
- BCDA N/A
- CARM $10,767,000.00
- Revenue This Year
- BCDA N/A
- CARM N/A
- Revenue Next Year
- BCDA N/A
- CARM N/A
- P/E Ratio
- BCDA N/A
- CARM N/A
- Revenue Growth
- BCDA N/A
- CARM N/A
- 52 Week Low
- BCDA $1.00
- CARM $0.14
- 52 Week High
- BCDA $3.20
- CARM $1.27
- Technical
- Relative Strength Index (RSI)
- BCDA 38.89
- CARM 44.09
- Support Level
- BCDA $1.27
- CARM $0.24
- Resistance Level
- BCDA $1.42
- CARM $0.27
- Average True Range (ATR)
- BCDA 0.11
- CARM 0.03
- MACD
- BCDA 0.01
- CARM -0.00
- Stochastic Oscillator
- BCDA 70.00
- CARM 26.11
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About CARM Carisma Therapeutics Inc.
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.